SCHEMBL18327652

SCHEMBL18327652

c1ccc(-c2ccnc(-c3ccc(-c4cc(-c5cnc6ccccc6c5)cc(-c5nc(-c6ccccc6)nc(-c6ccccc6)n5)c4)cc3)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 2/20 0.55
▸ PDGFRA P16234 2/20 0.55
▸ MAP4K4 O95819 2/20 0.49
▸ CSNK1G2 P78368 2/20 0.49
▸ CLK4 Q9HAZ1 2/20 0.49
▸ MKNK2 Q9HBH9 2/20 0.49
▸ MAP4K5 Q9Y4K4 1/20 0.49
▸ CYP2A6 P11509 1/20 0.49
▸ BIRC5 O15392 1/20 0.48
▸ PIK3CA P42336 3/20 0.47
▸ PIK3CD O00329 2/20 0.47
▸ PIK3CB P42338 1/20 0.47
▸ MTOR P42345 1/20 0.47
▸ PIK3CG P48736 1/20 0.47
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ MAPKAPK2 P49137 3/20 0.43
▸ PLK4 O00444 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18327540 0.96 PDGFRB (0.56) PDGFRBPDGFRAMAP4K4CSNK1G2CLK4
SCHEMBL18327373 0.88 MEN1 (0.50) MAP4K4PIM1MEN1ALDH1A1MAPT
SCHEMBL18327362 0.88 PDGFRB (0.60) PDGFRBPDGFRAMAP4K4CSNK1G2CLK4
SCHEMBL18327606 0.88 MEN1 (0.50) MAP4K4PIM1MEN1ALDH1A1MAPT
SCHEMBL19310448 0.88 PDGFRB (0.60) PDGFRBPDGFRAMAP4K4CSNK1G2CLK4
SCHEMBL18327313 0.86 PDGFRB (0.62) PDGFRBPDGFRAMAP4K4CSNK1G2CLK4
SCHEMBL18327466 0.85 PDGFRB (0.51) PDGFRBPDGFRAMAP4K4CSNK1G2CLK4
SCHEMBL26572251 0.84 BIRC5 (0.52) PDGFRBPDGFRAMAP4K4CSNK1G2CLK4
SCHEMBL18327601 0.84 MEN1 (0.46) MAP4K4PIM1NPC1MEN1ALDH1A1
SCHEMBL18327465 0.84 GABRA1 (0.51) PDGFRBPDGFRAPIK3CADYRK1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9812652-B2 Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component TOSOH CORPORATION (JP) 2017-11-07 — — US disclosed
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT TOSOH CORPORATION (JP) 2016-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT CHRM1, AFF1, AZI2 PDGFRB 1953/4885PDGFRA 1365/4885MAP4K4 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback